RDHL - RedHill Biopharma Ltd.
IEX Last Trade
6.55
0.125 1.908%
Share volume: 4
Last Updated: Thu 26 Dec 2024 08:26:39 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$6.42
0.13
1.95%
Fundamental analysis
15%
Profitability
15%
Dept financing
13%
Liquidity
75%
Performance
0%
Performance
5 Days
0.47%
1 Month
-19.72%
3 Months
-31.87%
6 Months
1,616.22%
1 Year
326.17%
2 Year
0.16%
Key data
Stock price
$6.55
DAY RANGE
$6.42 - $6.42
52 WEEK RANGE
$0.36 - $12.50
52 WEEK CHANGE
$331.97
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Dror Ben-Asher
Region: US
Website: redhillbio.com
Employees: 210
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: redhillbio.com
Employees: 210
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.
Recent news